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Toll-like receptors (TLRs) provoke a profound inflammatory response during host defense 
and must be controlled in order to avoid autoimmune and inflammatory diseases. In this 
issue, Rothlin et al. (2007) uncover a complex negative feedback mechanism to limit TLR 
signaling involving the Tyro3/Axl/Mer (TAM) family of receptor tyrosine kinases, which 
induce expression of the inhibitory proteins SOCS1 and SOCS3.Once unleashed, the innate immune 
response has the power to eliminate 
infections and provide instruction 
for the adaptive immune system to 
establish a memory response upon 
repeated exposure to the provoking 
pathogen. There has been remarkable 
progress toward the identification 
of receptors that recognize micro-
bial components during the innate 
immune response. Such receptors 
include the Toll-like receptors (TLRs), 
the NOD-like receptors (NLRs), the 
RIG-I-like receptors (RLRs), and the 
C-type lectin receptors (CLRs) (Cre-
agh and O’Neill, 2006; Brown, 2006). 
Activated TLRs induce a large number 
of immune and inflammatory proteins 
that are required for pathogen elimi-
nation. Because the ensuing inflam-
matory response has the potential to 
damage the host, multiple negative 
regulators modulate TLRs at various 
levels (Liew et al., 2005). An intriguing 
and potentially important mechanism 
of negative feedback is now reported 
by Rothlin et al. (2007) and implicates 
a hitherto poorly understood family of 
receptor tyrosine kinases termed the 
Tyro3/Axl/Mer (TAM) family (Lai and 
Lemke, 1991). The authors demon-
strate that TAM receptors are induced 
by TLRs and then in response to 
the TAM ligands, Gas6 and ProS, 
TAM receptor signaling induces the 
suppressor of cytokine signaling-1 
(SOCS1) protein and SOCS3, which 
act to limit TLR signaling. The eluci-
dation of this mechanism provides us 
with a greater understanding of how TLR signaling is regulated and pos-
sibly points to new approaches to 
curtail TLR activation during inflam-
matory and autoimmune diseases or 
to enhance TLR activation in order to 
boost the efficacy of vaccination.
TAM receptor tyrosine kinases 
were first found in neurons, where 
Tyro3 was shown to have a role in 
neural adhesion. Subsequently it was 
shown that loss of function of the three 
receptors in a triple knockout mouse 
resulted in a profound dysregulation 
of the immune response, including 
massive splenomegaly and lymph-
adenopathy, lymphocyte infiltration 
into all tissues, high autoantibody lev-
els, and broad spectrum autoimmune 
disease (Lu and Lemke, 2001). Sple-
nomegaly is also evident in mice lack-
ing only Mer. Importantly, these Mer-
deficient mice were also shown to be 
hypersensitive to the TLR4 agonist 
lipopolysaccharide (LPS) (Camenisch 
et al., 1999). It was hypothesized that 
this hypersensitivity was due to loss 
of inhibitory TAM signaling in den-
dritic cells, which are key participants 
in innate immune responses and also 
in the activation of T lymphocytes. 
To test this notion, Rothlin et al. first 
measured numbers of dendritic cells 
in TAM triple knockout mice using the 
commonly used dendritic cell marker 
CD11c; they found markedly elevated 
numbers of dendritic cells compared 
to wild-type mice. These dendritic 
cells also expressed high levels of 
activation markers, including MHC 
class II and the costimulatory mol-Cell 131, Decemecule B7.1. Dendritic cells from the 
triple knockout mice were hyperre-
sponsive to LPS, producing elevated 
levels of the cytokines interleukin-6 
and tumor necrosis factor relative to 
dendritic cells from wild-type mice. 
The hyperresponsiveness to LPS was 
progressively more severe in single, 
double, and triple knockout mice. The 
effect was not restricted to TLR4, as 
hyperresponsiveness was also seen 
to polyIC (a TLR3 ligand) and to CpG-
DNA (a TLR9 ligand).
The authors then examined the 
effect of the TAM ligands Gas6 and 
ProS. Pretreatment of dendritic cells 
overnight with these ligands inhibited 
cytokine induction by LPS, polyIC, 
and CpG, as well as activation of the 
TLR signals NF-κB, ERK1/2, and p38 
MAP kinase. The question then arose 
as to what might be the mechanism 
for this effect. The inhibitory effect 
was shown to require protein synthe-
sis, and the authors therefore looked 
for candidates that were known to 
inhibit TLRs and that were inducible. 
The SOCS1 protein was an obvious 
candidate because it is induced by 
cytokine receptors. Furthermore, 
knockout mice reconstituted with 
T lymphocytes expressing SOCS1 
develop an autoimmune phenotype 
very similar to that of TAM triple 
knockout mice (Hanada et al., 2003). 
SOCS3 was also tested, and both 
were shown to be induced in dendritic 
cells by TAM activation, whereas sev-
eral other negative regulators did not 
change.ber 14, 2007 ©2007 Elsevier Inc. 1039
Figure 1. Inhibition of TLR Signaling by TAM Receptors
Rothlin et al. (2007) propose a tripartite model for TLR action. In the first stage (1), an initial response is triggered by TLRs via adaptor proteins 
that lead to activation of TRAF3 and TRAF6. In turn, TRAF3 and TRAF6 activate the transcription factors IRF3 and NF-κB, respectively, leading to 
production of cytokines, notably type I interferons, which promote host defense and inflammation. In the second stage (2), interferon signaling has 
a positive feedforward effect, promoting further interferon production via STAT1, thereby amplifying the response. However, in the third stage (3), 
interferons also induce inhibitory TAM receptors via STAT1 in a negative feedback effect. The TAM receptor ligands Gas6 and ProS also activate 
STAT1, which selectively induces production of SOCS1 and SOCS3. These proteins mediate the inhibition of TLR signaling by targeting Mal in the 
case of SOCS1 and TRAF3 and TRAF6 in the case of SOCS3. Together, this process allows the innate immune response to be launched but ulti-
mately ensures that it is self-limiting and therefore not detrimental to the host.Rothlin and colleagues then 
probed the mechanism of SOCS1 
and SOCS3 induction by TAM recep-
tors. The transcription factor STAT1 
was shown to be essential for SOCS1 
and SOCS3 induction, as was the 
type I interferon receptor (IFNAR1). 
The TAM family member Axl was 
found to associate with the R1 chain 
of IFNAR1. Therefore, a new pathway 
involving the ligands Gas6 and ProS 
had been uncovered, and it activates 
STAT1 via TAM receptors in a complex 
with R1-IFNAR1, leading to the induc-
tion of SOCS1 and SOCS3. SOCS3 
likely prevents polyubiquitination of 
TRAF3 and TRAF6, key signaling pro-
teins activated by TLR3, TLR4, and 
TLR9. The final part of the mecha-
nism involves the induction of TAM 
receptors in response to TLR ligands. 
Intriguingly, this was also shown to 
depend on type I interferon signaling 
such that TLRs induce interferon-α, 
which activates STAT1 via IFNAR1, 1040 Cell 131, December 14, 2007 ©200leading to induction of TAM recep-
tors. The authors conclude that TAM 
receptors activate the terminal signal 
in what they term a tripartite inflam-
matory cycle. This cycle comprises 
the ignition of inflammation activated 
by TLRs, amplification of the signal by 
type I interferons (and other cytokines) 
in a positive feedforward mechanism, 
and finally TAM-mediated inhibition of 
TLR signaling in a negative feedback 
mechanism, which occurs via induc-
tion of SOCS1 and SOCS3 (Figure 1).
These events reveal the complex-
ity of TLR regulation. Inflammation 
is initiated by TLR signaling, which 
involves the production of a range of 
cytokines and chemokines to elicit the 
effector mechanisms of host defense. 
The cytokines can also trigger ampli-
fication in the overall responses, 
including enhancing their own induc-
tion. The transcription factor STAT1 
is particularly important here, as it is 
required for signaling by type I inter-7 Elsevier Inc.ferons. However, TAM receptors are 
also induced by cytokines and this 
induction (acting via STAT1) leads to 
increased expression of SOCS1 and 
SOCS3. SOCS1 targets the key TLR2 
and TLR4 adaptor protein Mal (Man-
sell et al., 2006), whereas SOCS3 
targets TRAF6 (used by all TLRs) 
and TRAF3 (used by TLR3 and TLR4) 
(Rothlin et al., 2007; Frobose et al., 
2006). Therefore, between SOCS1 
and SOCS3 there is the capacity to 
inhibit all TLRs.
The authors also conclude that the 
induction of SOCS1 by interferons 
can be almost wholly explained by 
TAM receptors. This prompts the first 
important question to arise from this 
study. What is the source of the TAM 
receptor ligands Gas6 and ProS? 
There is some evidence that they 
are autocrine factors, although this 
seems unlikely. The authors provide 
the interesting speculation that regu-
latory T cells, which are well-known 
inhibitors of TLRs, might be a source. 
The second question is why TAM 
receptors do not activate a range of 
STAT1-dependent genes. Instead, the 
effects of TAM receptors appear to be 
only inhibitory. The authors speculate 
about alternative effects on STAT1, 
but these require testing. Perhaps the 
IFNAR1/TAM receptor complex sig-
nals differently from IFNAR receptor 
complexes that bind to interferons. 
Related to this possibility, future work 
may address in detail how Axl inter-
acts with and regulates IFNAR1.
Given the importance of TLRs for 
the pathogenesis of autoimmune and 
inflammatory diseases, these findings 
will further stimulate efforts to modu-
late TLR activity. If the effects of the 
TAM receptor ligands Gas6 and ProS 
are specific to dendritic cells, these 
two factors might find use as anti-
inflammatory agents. Furthermore, 
hyperactive TAM signaling might To what extent is evolution repeat-
able? One classic way to address this 
issue is to ask whether evolutionary 
change occurs in parallel, that is do 
the same traits evolve repeatedly in 
disparate taxa? Evidence of parallel 
evolution at the phenotypic level has 
come from many studies of experi-
mental evolution in microbes (e.g., 
Travisano et al., 1995). These studies 
show overriding patterns of repeat-
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In this issue, Miller et al. (2007
to produce light pigmentation 
study indicates that analyzing
number of outstanding questiplay a role in sepsis by blocking host 
defense responses. Consistent with 
this notion, elevated levels of Gas6 
have been detected in patients with 
severe sepsis. An inhibitor of TAM 
receptors (such as a small molecule 
that blocks TAM receptor kinase 
activity) might potentiate immune 
responses in immunosuppressed 
patients. Such an inhibitor could also 
be used as a vaccine adjuvant as 
there is a pressing need to enhance 
the immunogenicity of candidate vac-
cine antigens.
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In this issue, Miller and col-
leagues (2007) tackle this question 
by exploring genetic mechanisms 
underlying pigmentation differences 
between marine and freshwater 
species of threespine stickleback 
fish (Gasterosteus species com-
plex). Sticklebacks are well known 
for their variation in color: from red 
and blue, to jet black, to translucent 
white. In the midst of large-scale 
alk Hand in 
eated use of the same genes 
leback fish and humans. This 
c level could help to answer a 
